Skip to main content
Clinical Trials/NCT04704076
NCT04704076
Completed
N/A

Preventing Infant Malnutrition With Early Supplementation, Aim 3

University of California, San Francisco2 sites in 2 countries324 target enrollmentFebruary 28, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Underweight
Sponsor
University of California, San Francisco
Enrollment
324
Locations
2
Primary Endpoint
Weight-for-age z-score (WAZ) at 30 days of age
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Background: Worldwide, more than 50 million children under 5 years of age are wasted (weight-for-length/height Z-score (WLZ) <-2) and over 150 million children under 5 are stunted (length/height-for-age Z-score (LAZ) <-2); such wasting and stunting often begin during infancy.1 Optimal nutrition can prevent wasting and stunting. Exclusive breastfeeding (EBF) is widely recommended by community health workers, doctors and nurses and provides optimal nutrition for most infants. However, early growth faltering is common for infants in low and middle income countries (LMIC) and can both increase an infant's risk of early mortality and also lead to deficits in attained height and weight throughout childhood. Thus research is needed to determine the most efficacious strategy to promote healthy early growth in LMIC.

Objective: The proposed study will test the efficacy of early small-volume supplementation (ESVS) for increasing weight-for-age z-score (WAZ) at 1 month of age.

Methodology: The PRIMES pilot (Study 3) will be a randomized clinical trial enrolling infants in Guinea-Bissau and Uganda weighing ≥2000g at birth. Infants weighing 2000-2499g at <6 hours of age (n=144; 72 per site) will be randomized on enrollment to one of two groups: 1) Early Small-Volume Supplementation (ESVS intervention group), which consists of up to 59 mL formula administered daily after breastfeeding through 30 days of age followed by EBF through 6 months of age; or 2) frequent exclusive breastfeeding without any food or fluid other than vitamins, minerals and medications (control) through 6 months of age. Infants weighing 2500-3300g at <6 hours of age will be weighed again at 4 days of age; those weighing <2600g at 4 days of age (n=180; 90 per site) will be randomized to the same intervention and control groups. Weight will be measured on all enrolled babies at birth on Day 1 and at 4, 14, 30, 60 and 180 days of age and additional measures including height, MUAC, skinfolds, and hemoglobin will be assessed at other time points. The study's primary outcome will be WAZ at 1 month of age. Secondary outcomes will include WLZ at 1 month of age; WAZ, WLZ and LAZ through 6 months of age; breastfeeding duration and infant intestinal microbiota.

Registry
clinicaltrials.gov
Start Date
February 28, 2021
End Date
January 31, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Infant \< 6 hours old
  • Infant birth weight 2000-2885g
  • Mother intends to breastfeed
  • Mother with negative HIV test
  • Mother lives in study catchment area and anticipates availability for all study visits
  • Mother ≥18 years old

Exclusion Criteria

  • Twins and other multiples
  • Infant with known major congenital anomalies including orofacial clefts, neural tube defects or congenital heart defects
  • Infant with WHO newborn and respiratory danger signs present:
  • Not feeding well
  • Convulsions
  • Very fast breathing ≥60 breaths/minute
  • Severe chest indrawing
  • No spontaneous movement
  • Lethargic or unconscious
  • Raised temperature \> 37.5 degrees Celsius

Outcomes

Primary Outcomes

Weight-for-age z-score (WAZ) at 30 days of age

Time Frame: 30 days of age

WAZ calculated according to WHO Child Growth Standards

Secondary Outcomes

  • Whether or not breastfeeding continues at 180 days of age(180 days of age)
  • Length-for-age z-score (LAZ) at 180 days of age(180 days of age)
  • Abundance of B.infantis in intestinal microbiota(180 days of age)
  • Neurodevelopment(365 days of age)
  • Brain volume(365 days of age)
  • Weight-for-length z-score (WLZ) at 30 days of age(30 days of age)
  • Weight-for-length z-score (WLZ) at 180 days of age(180 days of age)
  • Weight-for-age z-score (WLZ) at 180 days of age(180 days of age)
  • Weight-for-age z-score (WLZ) at 365 days of age(365 days of age)
  • Weight-for-length z-score (WLZ) at 365 days of age(365 days of age)
  • Length-for-age z-score (LAZ) at 365 days of age(365 days of age)
  • White matter volume(365 days of age)

Study Sites (2)

Loading locations...

Similar Trials